
Prediction: This Is What Eli Lilly Stock Will Do Next (Hint: It's Not a Stock Split)

I'm PortAI, I can summarize articles.
Eli Lilly (LLY) is the largest pharmaceutical company, with a market cap exceeding $200 billion, driven by growth from GLP-1 agonists like Mounjaro and Zepbound. Its stock has risen 58% in the past year, leading to speculation about a stock split, which is deemed unlikely. Instead, a dividend increase is anticipated, following historical trends of raising dividends in December. Investors are encouraged to consider buying shares for passive income, as Lilly is positioned for growth in various healthcare sectors, including diabetes and Alzheimer's treatments.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.

